WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study.
Abstract
Address
Biotigr Lab
Team 4 UMR-S 1134 INSERM
Université de Paris
Hôpital NECKER – Enfants Malades
149 rue de Sèvres
75015 Paris, France